EurekaMag.com logo
+ Site Statistics
References:
53,214,146
Abstracts:
29,074,682
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on Google+Follow on Google+
Follow on LinkedInFollow on LinkedIn

+ Translate

CME Part I Psoriasis: Which Therapy for Which Patient Psoriasis comorbidities and preferred systemic agents


Journal of the American Academy of Dermatology
CME Part I Psoriasis: Which Therapy for Which Patient Psoriasis comorbidities and preferred systemic agents
Psoriasis is a systemic inflammatory disease associated with increased risk of comorbidities such as psoriatic arthritis, Crohn disease, malignancy, obesity and cardiovascular diseases. All these factors have a significant impact on the decision to use one therapy over another. The past decade has seen a paradigm shift in our understanding of the pathogenesis of psoriasis which has led to identification of new therapeutic targets. Several new drugs have gained FDA approval, expanding the psoriasis armamentarium but still a large number of patients continue to be untreated or undertreated. Treatment regimens for psoriasis patients should be tailored to meet specific needs based on disease severity, impact on quality of life, response to previous therapies and presence of comorbidities. Part 1 of this CME article will focus on specific comorbidities and provide insights to choose appropriate systemic treatment in patients with moderate to severe psoriasis.

(PDF same-day service: $19.90)

Accession: 055116216

PMID: 30017705

DOI: 10.1016/j.jaad.2018.06.057



Related references

Etanercept therapy for psoriasis in a patient with numerous comorbidities. American Journal of Clinical Dermatology 11 Suppl 1: 49-50, 2010

From the Medical Board of the National Psoriasis Foundation: Perioperative management of systemic immunomodulatory agents in patients with psoriasis and psoriatic arthritis. Journal of the American Academy of Dermatology 75(4): 798-805.E7, 2016

National Psoriasis Foundation consensus statement on screening for latent tuberculosis infection in patients with psoriasis treated with systemic and biologic agents. Journal of the American Academy of Dermatology 59(2): 209-217, 2008

Evidence and Suggested Therapeutic Approach in Psoriasis of Difficult-to-treat Areas: Palmoplantar Psoriasis, Nail Psoriasis, Scalp Psoriasis, and Intertriginous Psoriasis. Indian Journal of Dermatology 62(2): 113-122, 2017

From the Medical Board of the National Psoriasis Foundation: Vaccination in adult patients on systemic therapy for psoriasis. Journal of the American Academy of Dermatology 69(6): 1003-1013, 2014

Psoriasis comorbidities: results from the National Psoriasis Foundation surveys 2003 to 2011. Dermatology 225(2): 121-126, 2013

Psoriasis vulgaris and psoriasis pustulosa - epidemiology, quality of life, comorbidities and treatment. Current Rheumatology Reviews 9(1): 2-7, 2013

National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening. Journal of the American Academy of Dermatology 58(6): 1031-1042, 2008

Integrated approach to comorbidity in patients with psoriasis.Working Group on Psoriasis-associated Comorbidities. Actas Dermo-Sifiliograficas 103 Suppl 1: 1-64, 2012

Psoriasis and increased drug utilization: a true burden of psoriasis or potential surveillance bias of comorbidities?. British Journal of Dermatology 176(3): 566-567, 2017